Cartesian Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Cartesian Therapeutics, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2019 to 2023.
  • Cartesian Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2022 was -$321K, a 102% decline year-over-year.
  • Cartesian Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$19M, a 3020% decline from 2022.
  • Cartesian Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$609K, a 104% decline from 2021.
  • Cartesian Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $16M.
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$19M -$18.4M -3020% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 -$609K -$16.6M -104% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 $16M +$16M Jan 1, 2021 Dec 31, 2021 10-K 2024-03-07
2020 $0 $0 Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 $0 Jan 1, 2019 Dec 31, 2019 10-K 2022-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.